Literature DB >> 30467067

Allogeneic hematopoietic cell transplantation; the current renaissance.

Edward A Copelan1, Aleksander Chojecki2, Hillard M Lazarus3, Belinda R Avalos2.   

Abstract

Allogeneic hematopoietic cell transplantation (HCT) provides the best chance for cure for many patients with malignant and nonmalignant hematologic disorders. Recent advances in selecting candidates and determining risk, procedure safety, utilization in older patients, use of alternative donors, and new or novel application of anti-cancer, immunosuppressive and antimicrobial agents have improved outcomes and expanded the role of HCT in hematologic disorders. Relapse remains the predominant cause of failure but enlightened use of new targeted and immunotherapeutic agents in combination with HCT promises to reduce relapse and further improve HCT outcomes.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; Conditioning; Graft-versus-host disease; Relapse

Mesh：

Year:  2018        PMID： 30467067     DOI： 10.1016/j.blre.2018.11.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN： 0268-960X            Impact factor:   8.250


  21 in total

1.  Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation.

Authors:  Angela Ricci; Zhezhen Jin; Larisa Broglie; Monica Bhatia; Diane George; James H Garvin; Matthew Hall; Prakash Satwani
Journal:  Bone Marrow Transplant       Date:  2019-09-19       Impact factor: 5.483

2.  How children's glue fixes a decades old enigma.

Authors:  Michael A Rieger
Journal:  Ann Transl Med       Date:  2019-12

3.  Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells.

Authors:  Attya Omer-Javed; Gabriele Pedrazzani; Luisa Albano; Sherash Ghaus; Claire Latroche; Maura Manzi; Samuele Ferrari; Martina Fiumara; Aurelien Jacob; Valentina Vavassori; Alessandro Nonis; Daniele Canarutto; Luigi Naldini
Journal:  Cell       Date:  2022-05-25       Impact factor: 66.850

4.  Safety and efficacy of a nonmyeloablative pretransplant conditioning regimen using total lymphoid irradiation with volumetric modulated arc therapy in healthy dogs: A pilot study.

Authors:  Sangho Kim; Kenji Hosoya; Natsuki Fukayama; Tatsuya Deguchi; Masahiro Okumura
Journal:  Vet Med Sci       Date:  2021-03-13

5.  Choices: peripheral blood or marrow: natural or cloned yeasts.

Authors:  Shaun R McCann
Journal:  Bone Marrow Transplant       Date:  2022-01-21       Impact factor: 5.483

Review 6.  The role of microbiota in allogeneic hematopoietic stem cell transplantation.

Authors:  Chia-Chi Chang; Eiko Hayase; Robert R Jenq
Journal:  Expert Opin Biol Ther       Date:  2021-01-18       Impact factor: 5.589

7.  Association between P2X7 Polymorphisms and Post-Transplant Outcomes in Allogeneic Haematopoietic Stem Cell Transplantation.

Authors:  Rachel M Koldej; Travis Perera; Jenny Collins; David S Ritchie
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

8.  Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years.

Authors:  Jakob R Passweg; Helen Baldomero; Christian Chabannon; Grzegorz W Basak; Rafael de la Cámara; Selim Corbacioglu; Harry Dolstra; Rafael Duarte; Bertram Glass; Raffaella Greco; Arjan C Lankester; Mohamad Mohty; Régis Peffault de Latour; John A Snowden; Ibrahim Yakoub-Agha; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2021-02-23       Impact factor: 5.483

Review 9.  Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.

Authors:  Jian Chen; Hillard M Lazarus; Parastoo B Dahi; Scott Avecilla; Sergio A Giralt
Journal:  Blood Rev       Date:  2020-10-31       Impact factor: 10.626

10.  Disrupted tongue microbiota and detection of nonindigenous bacteria on the day of allogeneic hematopoietic stem cell transplantation.

Authors:  Saori Oku; Toru Takeshita; Toshiko Futatsuki; Shinya Kageyama; Mikari Asakawa; Yasuo Mori; Toshihiro Miyamoto; Jun Hata; Toshiharu Ninomiya; Haruhiko Kashiwazaki; Yoshihisa Yamashita
Journal:  PLoS Pathog       Date:  2020-03-09       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.